nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Dinoprostone—PTGER4—multiple sclerosis	0.0103	1	CrCbGaD
Epoprostenol—PTGIR—brainstem—multiple sclerosis	0.00426	0.101	CbGeAlD
Epoprostenol—PTGIS—nervous system—multiple sclerosis	0.00389	0.0918	CbGeAlD
Epoprostenol—PTGIS—central nervous system—multiple sclerosis	0.00374	0.0884	CbGeAlD
Epoprostenol—PTGER1—nervous system—multiple sclerosis	0.00361	0.0853	CbGeAlD
Epoprostenol—P2RY12—nervous system—multiple sclerosis	0.0035	0.0827	CbGeAlD
Epoprostenol—PTGER1—central nervous system—multiple sclerosis	0.00348	0.0822	CbGeAlD
Epoprostenol—P2RY12—central nervous system—multiple sclerosis	0.00337	0.0796	CbGeAlD
Epoprostenol—PTGIS—brain—multiple sclerosis	0.00297	0.0702	CbGeAlD
Epoprostenol—P2RY12—brain—multiple sclerosis	0.00267	0.0632	CbGeAlD
Epoprostenol—PTGIR—spinal cord—multiple sclerosis	0.00265	0.0626	CbGeAlD
Epoprostenol—PTGIR—nervous system—multiple sclerosis	0.00223	0.0527	CbGeAlD
Epoprostenol—PTGIR—central nervous system—multiple sclerosis	0.00215	0.0508	CbGeAlD
Epoprostenol—PTGIR—cerebellum—multiple sclerosis	0.0021	0.0496	CbGeAlD
Epoprostenol—PTGIR—brain—multiple sclerosis	0.00171	0.0403	CbGeAlD
Epoprostenol—Urticaria—Mitoxantrone—multiple sclerosis	0.000672	0.00133	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000671	0.00133	CcSEcCtD
Epoprostenol—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000668	0.00132	CcSEcCtD
Epoprostenol—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000668	0.00132	CcSEcCtD
Epoprostenol—Myalgia—Triamcinolone—multiple sclerosis	0.000665	0.00132	CcSEcCtD
Epoprostenol—Vomiting—Azathioprine—multiple sclerosis	0.000665	0.00132	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—multiple sclerosis	0.000664	0.00131	CcSEcCtD
Epoprostenol—Arthralgia—Methylprednisolone—multiple sclerosis	0.000664	0.00131	CcSEcCtD
Epoprostenol—Myalgia—Methylprednisolone—multiple sclerosis	0.000664	0.00131	CcSEcCtD
Epoprostenol—Anxiety—Methylprednisolone—multiple sclerosis	0.000662	0.00131	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—multiple sclerosis	0.000661	0.00131	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—multiple sclerosis	0.000661	0.00131	CcSEcCtD
Epoprostenol—Rash—Azathioprine—multiple sclerosis	0.000659	0.0013	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000659	0.0013	CcSEcCtD
Epoprostenol—Dermatitis—Azathioprine—multiple sclerosis	0.000659	0.0013	CcSEcCtD
Epoprostenol—Depression—Methotrexate—multiple sclerosis	0.000659	0.0013	CcSEcCtD
Epoprostenol—Flushing—Prednisone—multiple sclerosis	0.000658	0.0013	CcSEcCtD
Epoprostenol—Headache—Azathioprine—multiple sclerosis	0.000655	0.0013	CcSEcCtD
Epoprostenol—Dry mouth—Triamcinolone—multiple sclerosis	0.000651	0.00129	CcSEcCtD
Epoprostenol—Angiopathy—Prednisone—multiple sclerosis	0.000644	0.00127	CcSEcCtD
Epoprostenol—Confusional state—Methylprednisolone—multiple sclerosis	0.000642	0.00127	CcSEcCtD
Epoprostenol—Oedema—Triamcinolone—multiple sclerosis	0.000638	0.00126	CcSEcCtD
Epoprostenol—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000638	0.00126	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000637	0.00126	CcSEcCtD
Epoprostenol—Syncope—Dexamethasone—multiple sclerosis	0.000636	0.00126	CcSEcCtD
Epoprostenol—Syncope—Betamethasone—multiple sclerosis	0.000636	0.00126	CcSEcCtD
Epoprostenol—Infection—Triamcinolone—multiple sclerosis	0.000634	0.00125	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—multiple sclerosis	0.000633	0.00125	CcSEcCtD
Epoprostenol—Infection—Methylprednisolone—multiple sclerosis	0.000632	0.00125	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—multiple sclerosis	0.00063	0.00125	CcSEcCtD
Epoprostenol—Shock—Triamcinolone—multiple sclerosis	0.000628	0.00124	CcSEcCtD
Epoprostenol—Insomnia—Prednisolone—multiple sclerosis	0.000627	0.00124	CcSEcCtD
Epoprostenol—Shock—Methylprednisolone—multiple sclerosis	0.000626	0.00124	CcSEcCtD
Epoprostenol—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000624	0.00124	CcSEcCtD
Epoprostenol—Loss of consciousness—Betamethasone—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisolone—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Tachycardia—Triamcinolone—multiple sclerosis	0.000623	0.00123	CcSEcCtD
Epoprostenol—Mental disorder—Prednisone—multiple sclerosis	0.000622	0.00123	CcSEcCtD
Epoprostenol—Nausea—Azathioprine—multiple sclerosis	0.000621	0.00123	CcSEcCtD
Epoprostenol—Tachycardia—Methylprednisolone—multiple sclerosis	0.000621	0.00123	CcSEcCtD
Epoprostenol—Skin disorder—Methylprednisolone—multiple sclerosis	0.000618	0.00122	CcSEcCtD
Epoprostenol—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000617	0.00122	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000615	0.00122	CcSEcCtD
Epoprostenol—Asthenia—Mitoxantrone—multiple sclerosis	0.000607	0.0012	CcSEcCtD
Epoprostenol—Myalgia—Betamethasone—multiple sclerosis	0.000604	0.00119	CcSEcCtD
Epoprostenol—Myalgia—Dexamethasone—multiple sclerosis	0.000604	0.00119	CcSEcCtD
Epoprostenol—Anxiety—Dexamethasone—multiple sclerosis	0.000602	0.00119	CcSEcCtD
Epoprostenol—Anxiety—Betamethasone—multiple sclerosis	0.000602	0.00119	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—multiple sclerosis	0.000596	0.00118	CcSEcCtD
Epoprostenol—Hypotension—Methylprednisolone—multiple sclerosis	0.000595	0.00118	CcSEcCtD
Epoprostenol—Pain—Prednisolone—multiple sclerosis	0.000593	0.00117	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—multiple sclerosis	0.000593	0.00117	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—multiple sclerosis	0.000589	0.00116	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000581	0.00115	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00058	0.00115	CcSEcCtD
Epoprostenol—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000579	0.00115	CcSEcCtD
Epoprostenol—Oedema—Dexamethasone—multiple sclerosis	0.000579	0.00115	CcSEcCtD
Epoprostenol—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000579	0.00115	CcSEcCtD
Epoprostenol—Oedema—Betamethasone—multiple sclerosis	0.000579	0.00115	CcSEcCtD
Epoprostenol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000579	0.00114	CcSEcCtD
Epoprostenol—Insomnia—Triamcinolone—multiple sclerosis	0.000577	0.00114	CcSEcCtD
Epoprostenol—Insomnia—Methylprednisolone—multiple sclerosis	0.000576	0.00114	CcSEcCtD
Epoprostenol—Infection—Dexamethasone—multiple sclerosis	0.000575	0.00114	CcSEcCtD
Epoprostenol—Infection—Betamethasone—multiple sclerosis	0.000575	0.00114	CcSEcCtD
Epoprostenol—Paraesthesia—Triamcinolone—multiple sclerosis	0.000573	0.00113	CcSEcCtD
Epoprostenol—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000572	0.00113	CcSEcCtD
Epoprostenol—Anaemia—Prednisone—multiple sclerosis	0.000571	0.00113	CcSEcCtD
Epoprostenol—Shock—Betamethasone—multiple sclerosis	0.000569	0.00113	CcSEcCtD
Epoprostenol—Shock—Dexamethasone—multiple sclerosis	0.000569	0.00113	CcSEcCtD
Epoprostenol—Dyspnoea—Triamcinolone—multiple sclerosis	0.000569	0.00113	CcSEcCtD
Epoprostenol—Nervous system disorder—Betamethasone—multiple sclerosis	0.000568	0.00112	CcSEcCtD
Epoprostenol—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000568	0.00112	CcSEcCtD
Epoprostenol—Agitation—Prednisone—multiple sclerosis	0.000568	0.00112	CcSEcCtD
Epoprostenol—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000567	0.00112	CcSEcCtD
Epoprostenol—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000567	0.00112	CcSEcCtD
Epoprostenol—Tachycardia—Betamethasone—multiple sclerosis	0.000565	0.00112	CcSEcCtD
Epoprostenol—Tachycardia—Dexamethasone—multiple sclerosis	0.000565	0.00112	CcSEcCtD
Epoprostenol—Dyspepsia—Triamcinolone—multiple sclerosis	0.000562	0.00111	CcSEcCtD
Epoprostenol—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00056	0.00111	CcSEcCtD
Epoprostenol—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00056	0.00111	CcSEcCtD
Epoprostenol—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00056	0.00111	CcSEcCtD
Epoprostenol—Syncope—Prednisone—multiple sclerosis	0.000554	0.0011	CcSEcCtD
Epoprostenol—Anorexia—Dexamethasone—multiple sclerosis	0.000552	0.00109	CcSEcCtD
Epoprostenol—Anorexia—Betamethasone—multiple sclerosis	0.000552	0.00109	CcSEcCtD
Epoprostenol—Urticaria—Prednisolone—multiple sclerosis	0.000551	0.00109	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—multiple sclerosis	0.00055	0.00109	CcSEcCtD
Epoprostenol—Fatigue—Triamcinolone—multiple sclerosis	0.00055	0.00109	CcSEcCtD
Epoprostenol—Fatigue—Methylprednisolone—multiple sclerosis	0.000549	0.00109	CcSEcCtD
Epoprostenol—Pain—Triamcinolone—multiple sclerosis	0.000546	0.00108	CcSEcCtD
Epoprostenol—Loss of consciousness—Prednisone—multiple sclerosis	0.000543	0.00107	CcSEcCtD
Epoprostenol—Hypotension—Dexamethasone—multiple sclerosis	0.000541	0.00107	CcSEcCtD
Epoprostenol—Hypotension—Betamethasone—multiple sclerosis	0.000541	0.00107	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—multiple sclerosis	0.000538	0.00106	CcSEcCtD
Epoprostenol—Vomiting—Mitoxantrone—multiple sclerosis	0.000538	0.00106	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000534	0.00106	CcSEcCtD
Epoprostenol—Rash—Mitoxantrone—multiple sclerosis	0.000533	0.00105	CcSEcCtD
Epoprostenol—Dermatitis—Mitoxantrone—multiple sclerosis	0.000533	0.00105	CcSEcCtD
Epoprostenol—Chills—Methotrexate—multiple sclerosis	0.000532	0.00105	CcSEcCtD
Epoprostenol—Headache—Mitoxantrone—multiple sclerosis	0.00053	0.00105	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000527	0.00104	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000527	0.00104	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—multiple sclerosis	0.000526	0.00104	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—multiple sclerosis	0.000526	0.00104	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—multiple sclerosis	0.000524	0.00104	CcSEcCtD
Epoprostenol—Insomnia—Betamethasone—multiple sclerosis	0.000524	0.00104	CcSEcCtD
Epoprostenol—Insomnia—Dexamethasone—multiple sclerosis	0.000524	0.00104	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000522	0.00103	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00052	0.00103	CcSEcCtD
Epoprostenol—Paraesthesia—Dexamethasone—multiple sclerosis	0.00052	0.00103	CcSEcCtD
Epoprostenol—Paraesthesia—Betamethasone—multiple sclerosis	0.00052	0.00103	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—multiple sclerosis	0.00052	0.00103	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000519	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL13—multiple sclerosis	0.000519	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR1—multiple sclerosis	0.000519	0.00117	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR1—multiple sclerosis	0.000519	0.00117	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000517	0.00117	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TAGAP—multiple sclerosis	0.000517	0.00117	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—IL6—multiple sclerosis	0.000516	0.00117	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RPL5—multiple sclerosis	0.000513	0.00116	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Prednisolone—multiple sclerosis	0.000511	0.00101	CcSEcCtD
Epoprostenol—Dyspepsia—Betamethasone—multiple sclerosis	0.00051	0.00101	CcSEcCtD
Epoprostenol—Dyspepsia—Dexamethasone—multiple sclerosis	0.00051	0.00101	CcSEcCtD
Epoprostenol—Urticaria—Triamcinolone—multiple sclerosis	0.000507	0.001	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCL5—multiple sclerosis	0.000506	0.00114	CbGpPWpGaD
Epoprostenol—Urticaria—Methylprednisolone—multiple sclerosis	0.000506	0.001	CcSEcCtD
Epoprostenol—Body temperature increased—Triamcinolone—multiple sclerosis	0.000504	0.000998	CcSEcCtD
Epoprostenol—Oedema—Prednisone—multiple sclerosis	0.000504	0.000997	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—multiple sclerosis	0.000504	0.000997	CcSEcCtD
Epoprostenol—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000503	0.000996	CcSEcCtD
Epoprostenol—Decreased appetite—Dexamethasone—multiple sclerosis	0.000503	0.000996	CcSEcCtD
Epoprostenol—Decreased appetite—Betamethasone—multiple sclerosis	0.000503	0.000996	CcSEcCtD
Epoprostenol—Nausea—Mitoxantrone—multiple sclerosis	0.000502	0.000994	CcSEcCtD
Epoprostenol—Infection—Prednisone—multiple sclerosis	0.000501	0.000991	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.0005	0.000989	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.0005	0.000989	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—multiple sclerosis	0.000499	0.000988	CcSEcCtD
Epoprostenol—Fatigue—Betamethasone—multiple sclerosis	0.000499	0.000987	CcSEcCtD
Epoprostenol—Fatigue—Dexamethasone—multiple sclerosis	0.000499	0.000987	CcSEcCtD
Epoprostenol—Shock—Prednisone—multiple sclerosis	0.000496	0.000981	CcSEcCtD
Epoprostenol—Pain—Betamethasone—multiple sclerosis	0.000495	0.000979	CcSEcCtD
Epoprostenol—Pain—Dexamethasone—multiple sclerosis	0.000495	0.000979	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—multiple sclerosis	0.000494	0.000978	CcSEcCtD
Epoprostenol—Tachycardia—Prednisone—multiple sclerosis	0.000492	0.000973	CcSEcCtD
Epoprostenol—PTGIS—Disease—SLC11A1—multiple sclerosis	0.000491	0.00111	CbGpPWpGaD
Epoprostenol—Skin disorder—Prednisone—multiple sclerosis	0.00049	0.000969	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—multiple sclerosis	0.000487	0.000964	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—multiple sclerosis	0.000481	0.000951	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—multiple sclerosis	0.000477	0.000944	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—TAGAP—multiple sclerosis	0.000475	0.00108	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TAGAP—multiple sclerosis	0.000475	0.00108	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000473	0.000936	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000473	0.000936	CcSEcCtD
Epoprostenol—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00047	0.00093	CcSEcCtD
Epoprostenol—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000469	0.000928	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000468	0.00106	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL5—multiple sclerosis	0.000466	0.00105	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL5—multiple sclerosis	0.000466	0.00105	CbGpPWpGaD
Epoprostenol—Urticaria—Betamethasone—multiple sclerosis	0.00046	0.00091	CcSEcCtD
Epoprostenol—Urticaria—Dexamethasone—multiple sclerosis	0.00046	0.00091	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000459	0.000909	CcSEcCtD
Epoprostenol—Dizziness—Prednisolone—multiple sclerosis	0.000459	0.000908	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000458	0.00104	CbGpPWpGaD
Epoprostenol—Asthenia—Triamcinolone—multiple sclerosis	0.000458	0.000906	CcSEcCtD
Epoprostenol—Abdominal pain—Betamethasone—multiple sclerosis	0.000458	0.000905	CcSEcCtD
Epoprostenol—Abdominal pain—Dexamethasone—multiple sclerosis	0.000458	0.000905	CcSEcCtD
Epoprostenol—Body temperature increased—Betamethasone—multiple sclerosis	0.000458	0.000905	CcSEcCtD
Epoprostenol—Body temperature increased—Dexamethasone—multiple sclerosis	0.000458	0.000905	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000457	0.00103	CbGpPWpGaD
Epoprostenol—Asthenia—Methylprednisolone—multiple sclerosis	0.000457	0.000904	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—multiple sclerosis	0.000456	0.000902	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCR5—multiple sclerosis	0.000456	0.00103	CbGpPWpGaD
Epoprostenol—Paraesthesia—Prednisone—multiple sclerosis	0.000453	0.000896	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—S1PR1—multiple sclerosis	0.000451	0.00102	CbGpPWpGaD
Epoprostenol—Pruritus—Triamcinolone—multiple sclerosis	0.000451	0.000893	CcSEcCtD
Epoprostenol—Cough—Methotrexate—multiple sclerosis	0.00045	0.000891	CcSEcCtD
Epoprostenol—Pruritus—Methylprednisolone—multiple sclerosis	0.00045	0.000891	CcSEcCtD
Epoprostenol—Dyspepsia—Prednisone—multiple sclerosis	0.000444	0.000878	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—multiple sclerosis	0.000439	0.000869	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—multiple sclerosis	0.000439	0.000869	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—multiple sclerosis	0.000439	0.000869	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—GPC5—multiple sclerosis	0.000439	0.000994	CbGpPWpGaD
Epoprostenol—Decreased appetite—Prednisone—multiple sclerosis	0.000438	0.000867	CcSEcCtD
Epoprostenol—Rash—Prednisolone—multiple sclerosis	0.000437	0.000865	CcSEcCtD
Epoprostenol—Dermatitis—Prednisolone—multiple sclerosis	0.000437	0.000865	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000436	0.000864	CcSEcCtD
Epoprostenol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000436	0.000862	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—multiple sclerosis	0.000435	0.00086	CcSEcCtD
Epoprostenol—Headache—Prednisolone—multiple sclerosis	0.000435	0.00086	CcSEcCtD
Epoprostenol—Constipation—Prednisone—multiple sclerosis	0.000431	0.000853	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000431	0.000974	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000431	0.000974	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000426	0.000963	CbGpPWpGaD
Epoprostenol—Confusional state—Methotrexate—multiple sclerosis	0.000425	0.00084	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000425	0.000961	CbGpPWpGaD
Epoprostenol—Dizziness—Triamcinolone—multiple sclerosis	0.000422	0.000835	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000421	0.000953	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000421	0.000953	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000421	0.000834	CcSEcCtD
Epoprostenol—Dizziness—Methylprednisolone—multiple sclerosis	0.000421	0.000833	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCR5—multiple sclerosis	0.00042	0.000949	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCR5—multiple sclerosis	0.00042	0.000949	CbGpPWpGaD
Epoprostenol—Infection—Methotrexate—multiple sclerosis	0.000419	0.000828	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—S1PR1—multiple sclerosis	0.000415	0.00094	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—S1PR1—multiple sclerosis	0.000415	0.00094	CbGpPWpGaD
Epoprostenol—Asthenia—Dexamethasone—multiple sclerosis	0.000415	0.000822	CcSEcCtD
Epoprostenol—Asthenia—Betamethasone—multiple sclerosis	0.000415	0.000822	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—multiple sclerosis	0.000413	0.000817	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000412	0.000816	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000412	0.000816	CcSEcCtD
Epoprostenol—Nausea—Prednisolone—multiple sclerosis	0.000412	0.000815	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000411	0.00093	CbGpPWpGaD
Epoprostenol—Pruritus—Dexamethasone—multiple sclerosis	0.00041	0.00081	CcSEcCtD
Epoprostenol—Pruritus—Betamethasone—multiple sclerosis	0.00041	0.00081	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—multiple sclerosis	0.000409	0.00081	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000407	0.000806	CcSEcCtD
Epoprostenol—Vomiting—Triamcinolone—multiple sclerosis	0.000406	0.000803	CcSEcCtD
Epoprostenol—Vomiting—Methylprednisolone—multiple sclerosis	0.000405	0.000801	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—GPC5—multiple sclerosis	0.000404	0.000914	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GPC5—multiple sclerosis	0.000404	0.000914	CbGpPWpGaD
Epoprostenol—Rash—Triamcinolone—multiple sclerosis	0.000402	0.000796	CcSEcCtD
Epoprostenol—Dermatitis—Triamcinolone—multiple sclerosis	0.000402	0.000795	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IL2RA—multiple sclerosis	0.000402	0.000909	CbGpPWpGaD
Epoprostenol—Anorexia—Methotrexate—multiple sclerosis	0.000402	0.000795	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCL3—multiple sclerosis	0.000401	0.000908	CbGpPWpGaD
Epoprostenol—Rash—Methylprednisolone—multiple sclerosis	0.000401	0.000794	CcSEcCtD
Epoprostenol—Dermatitis—Methylprednisolone—multiple sclerosis	0.000401	0.000793	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—multiple sclerosis	0.0004	0.000792	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR2—multiple sclerosis	0.0004	0.000905	CbGpPWpGaD
Epoprostenol—Headache—Triamcinolone—multiple sclerosis	0.0004	0.000791	CcSEcCtD
Epoprostenol—Headache—Methylprednisolone—multiple sclerosis	0.000399	0.000789	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—multiple sclerosis	0.000398	0.000788	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—multiple sclerosis	0.000398	0.000788	CcSEcCtD
Epoprostenol—Diarrhoea—Dexamethasone—multiple sclerosis	0.000396	0.000784	CcSEcCtD
Epoprostenol—Diarrhoea—Betamethasone—multiple sclerosis	0.000396	0.000784	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—multiple sclerosis	0.000394	0.000779	CcSEcCtD
Epoprostenol—PTGIS—Disease—CD28—multiple sclerosis	0.000392	0.000887	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000392	0.000886	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000392	0.000886	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PTGER4—multiple sclerosis	0.000386	0.000874	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RGS1—multiple sclerosis	0.000384	0.000869	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000384	0.000759	CcSEcCtD
Epoprostenol—Dizziness—Dexamethasone—multiple sclerosis	0.000383	0.000757	CcSEcCtD
Epoprostenol—Dizziness—Betamethasone—multiple sclerosis	0.000383	0.000757	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—multiple sclerosis	0.000381	0.000754	CcSEcCtD
Epoprostenol—Nausea—Triamcinolone—multiple sclerosis	0.000379	0.00075	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—multiple sclerosis	0.000378	0.000748	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000378	0.000856	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000378	0.000856	CbGpPWpGaD
Epoprostenol—Nausea—Methylprednisolone—multiple sclerosis	0.000378	0.000748	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—multiple sclerosis	0.000376	0.000743	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—multiple sclerosis	0.000375	0.000741	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CXCR3—multiple sclerosis	0.000373	0.000844	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Prednisone—multiple sclerosis	0.000371	0.000735	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—multiple sclerosis	0.000371	0.000734	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IL2RA—multiple sclerosis	0.00037	0.000837	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL3—multiple sclerosis	0.000369	0.000836	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL3—multiple sclerosis	0.000369	0.000836	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CNR1—multiple sclerosis	0.000369	0.000835	CbGpPWpGaD
Epoprostenol—Vomiting—Betamethasone—multiple sclerosis	0.000368	0.000728	CcSEcCtD
Epoprostenol—Vomiting—Dexamethasone—multiple sclerosis	0.000368	0.000728	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR2—multiple sclerosis	0.000368	0.000832	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000368	0.000832	CbGpPWpGaD
Epoprostenol—Decreased appetite—Methotrexate—multiple sclerosis	0.000366	0.000725	CcSEcCtD
Epoprostenol—Rash—Dexamethasone—multiple sclerosis	0.000365	0.000722	CcSEcCtD
Epoprostenol—Rash—Betamethasone—multiple sclerosis	0.000365	0.000722	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000365	0.000825	CbGpPWpGaD
Epoprostenol—Dermatitis—Dexamethasone—multiple sclerosis	0.000365	0.000721	CcSEcCtD
Epoprostenol—Dermatitis—Betamethasone—multiple sclerosis	0.000365	0.000721	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—GPR65—multiple sclerosis	0.000364	0.000823	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000364	0.00072	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—multiple sclerosis	0.000363	0.000719	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCR2—multiple sclerosis	0.000363	0.000821	CbGpPWpGaD
Epoprostenol—Headache—Betamethasone—multiple sclerosis	0.000363	0.000717	CcSEcCtD
Epoprostenol—Headache—Dexamethasone—multiple sclerosis	0.000363	0.000717	CcSEcCtD
Epoprostenol—Asthenia—Prednisone—multiple sclerosis	0.000362	0.000716	CcSEcCtD
Epoprostenol—Pain—Methotrexate—multiple sclerosis	0.00036	0.000713	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—multiple sclerosis	0.000357	0.000706	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000356	0.000806	CbGpPWpGaD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000356	0.000806	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—POMC—multiple sclerosis	0.000356	0.000806	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTGER4—multiple sclerosis	0.000356	0.000805	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000356	0.000805	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RGS1—multiple sclerosis	0.000353	0.000799	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RGS1—multiple sclerosis	0.000353	0.000799	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.00035	0.000791	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCL2—multiple sclerosis	0.000349	0.000789	CbGpPWpGaD
Epoprostenol—Diarrhoea—Prednisone—multiple sclerosis	0.000345	0.000682	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000344	0.000682	CcSEcCtD
Epoprostenol—Nausea—Dexamethasone—multiple sclerosis	0.000344	0.00068	CcSEcCtD
Epoprostenol—Nausea—Betamethasone—multiple sclerosis	0.000344	0.00068	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CXCR3—multiple sclerosis	0.000343	0.000777	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000343	0.000777	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CNR1—multiple sclerosis	0.00034	0.000768	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CNR1—multiple sclerosis	0.00034	0.000768	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CNR1—multiple sclerosis	0.000335	0.000758	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GPR65—multiple sclerosis	0.000335	0.000758	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GPR65—multiple sclerosis	0.000335	0.000758	CbGpPWpGaD
Epoprostenol—Urticaria—Methotrexate—multiple sclerosis	0.000335	0.000662	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CCR2—multiple sclerosis	0.000334	0.000756	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR2—multiple sclerosis	0.000334	0.000756	CbGpPWpGaD
Epoprostenol—Dizziness—Prednisone—multiple sclerosis	0.000333	0.00066	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—multiple sclerosis	0.000333	0.000659	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—multiple sclerosis	0.000333	0.000659	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CCR1—multiple sclerosis	0.000333	0.000753	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL13—multiple sclerosis	0.000333	0.000753	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000333	0.000752	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000332	0.000752	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000329	0.000744	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—POMC—multiple sclerosis	0.000328	0.000742	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—POMC—multiple sclerosis	0.000328	0.000742	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL2—multiple sclerosis	0.000321	0.000726	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL2—multiple sclerosis	0.000321	0.000726	CbGpPWpGaD
Epoprostenol—Vomiting—Prednisone—multiple sclerosis	0.000321	0.000634	CcSEcCtD
Epoprostenol—Rash—Prednisone—multiple sclerosis	0.000318	0.000629	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—multiple sclerosis	0.000318	0.000628	CcSEcCtD
Epoprostenol—Headache—Prednisone—multiple sclerosis	0.000316	0.000625	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—BCHE—multiple sclerosis	0.000314	0.000711	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Methotrexate—multiple sclerosis	0.00031	0.000614	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CNR1—multiple sclerosis	0.000308	0.000698	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CNR1—multiple sclerosis	0.000308	0.000698	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL13—multiple sclerosis	0.000306	0.000693	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR1—multiple sclerosis	0.000306	0.000693	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR1—multiple sclerosis	0.000306	0.000693	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL13—multiple sclerosis	0.000306	0.000693	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000306	0.000692	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000306	0.000692	CbGpPWpGaD
Epoprostenol—Asthenia—Methotrexate—multiple sclerosis	0.000302	0.000598	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL10—multiple sclerosis	0.000302	0.000683	CbGpPWpGaD
Epoprostenol—Nausea—Prednisone—multiple sclerosis	0.000299	0.000592	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—multiple sclerosis	0.000298	0.00059	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—ALB—multiple sclerosis	0.00029	0.000657	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000289	0.000654	CbGpPWpGaD
Epoprostenol—Diarrhoea—Methotrexate—multiple sclerosis	0.000288	0.00057	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CCL5—multiple sclerosis	0.000286	0.000647	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD86—multiple sclerosis	0.00028	0.000633	CbGpPWpGaD
Epoprostenol—Dizziness—Methotrexate—multiple sclerosis	0.000279	0.000551	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL10—multiple sclerosis	0.000278	0.000628	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000278	0.000628	CbGpPWpGaD
Epoprostenol—Vomiting—Methotrexate—multiple sclerosis	0.000268	0.00053	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—ALB—multiple sclerosis	0.000267	0.000605	CbGpPWpGaD
Epoprostenol—Rash—Methotrexate—multiple sclerosis	0.000266	0.000526	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—multiple sclerosis	0.000265	0.000525	CcSEcCtD
Epoprostenol—Headache—Methotrexate—multiple sclerosis	0.000264	0.000522	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CCL5—multiple sclerosis	0.000263	0.000595	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000263	0.000595	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000262	0.000593	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000262	0.000593	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL5—multiple sclerosis	0.00026	0.000588	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR5—multiple sclerosis	0.000258	0.000583	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000254	0.000574	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000253	0.000572	CbGpPWpGaD
Epoprostenol—Nausea—Methotrexate—multiple sclerosis	0.00025	0.000495	CcSEcCtD
Epoprostenol—PTGIS—Disease—CCR5—multiple sclerosis	0.000248	0.000561	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HLA-A—multiple sclerosis	0.000242	0.000547	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL5—multiple sclerosis	0.000239	0.000541	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL5—multiple sclerosis	0.000239	0.000541	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL3—multiple sclerosis	0.000237	0.000537	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR5—multiple sclerosis	0.000237	0.000536	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000237	0.000536	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IL2—multiple sclerosis	0.000236	0.000533	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCR5—multiple sclerosis	0.000234	0.000529	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000234	0.000529	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000234	0.000529	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2RA—multiple sclerosis	0.000231	0.000522	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTGER4—multiple sclerosis	0.000228	0.000516	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOE—multiple sclerosis	0.000226	0.000511	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PGR—multiple sclerosis	0.000225	0.000509	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCR3—multiple sclerosis	0.00022	0.000499	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CD28—multiple sclerosis	0.000218	0.000494	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL3—multiple sclerosis	0.000218	0.000494	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL3—multiple sclerosis	0.000218	0.000494	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—multiple sclerosis	0.000217	0.00049	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR5—multiple sclerosis	0.000215	0.000487	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR5—multiple sclerosis	0.000215	0.000487	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR2—multiple sclerosis	0.000214	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2RA—multiple sclerosis	0.000212	0.00048	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000212	0.00048	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTGER4—multiple sclerosis	0.00021	0.000475	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTGER4—multiple sclerosis	0.00021	0.000475	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PGR—multiple sclerosis	0.000207	0.000468	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PGR—multiple sclerosis	0.000207	0.000468	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD80—multiple sclerosis	0.000204	0.000462	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCR3—multiple sclerosis	0.000203	0.000459	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCR3—multiple sclerosis	0.000203	0.000459	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—POMC—multiple sclerosis	0.000201	0.000456	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CD28—multiple sclerosis	0.000201	0.000455	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CD28—multiple sclerosis	0.000201	0.000455	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CNR1—multiple sclerosis	0.000198	0.000448	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR2—multiple sclerosis	0.000197	0.000447	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR2—multiple sclerosis	0.000197	0.000447	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—APOE—multiple sclerosis	0.000189	0.000428	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—POMC—multiple sclerosis	0.000185	0.000419	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—POMC—multiple sclerosis	0.000185	0.000419	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—multiple sclerosis	0.000184	0.000416	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—POMC—multiple sclerosis	0.000183	0.000414	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CNR1—multiple sclerosis	0.000182	0.000412	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CNR1—multiple sclerosis	0.000182	0.000412	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK1—multiple sclerosis	0.00018	0.000408	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL2—multiple sclerosis	0.000179	0.000405	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL10—multiple sclerosis	0.000178	0.000403	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TYK2—multiple sclerosis	0.000172	0.00039	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—multiple sclerosis	0.000169	0.000383	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—POMC—multiple sclerosis	0.000168	0.000381	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—POMC—multiple sclerosis	0.000168	0.000381	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK1—multiple sclerosis	0.000166	0.000375	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SRM—multiple sclerosis	0.000166	0.000375	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL2—multiple sclerosis	0.000165	0.000373	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL2—multiple sclerosis	0.000165	0.000373	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL10—multiple sclerosis	0.000164	0.000371	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL10—multiple sclerosis	0.000164	0.000371	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—TYK2—multiple sclerosis	0.000162	0.000368	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—POMC—multiple sclerosis	0.000162	0.000367	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CD86—multiple sclerosis	0.000156	0.000353	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—multiple sclerosis	0.000156	0.000353	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—POMC—multiple sclerosis	0.000153	0.000347	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL5—multiple sclerosis	0.000153	0.000347	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—TYK2—multiple sclerosis	0.00015	0.000338	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—TYK2—multiple sclerosis	0.00015	0.000338	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—multiple sclerosis	0.000149	0.000337	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—multiple sclerosis	0.000148	0.000335	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CD86—multiple sclerosis	0.000143	0.000324	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CD86—multiple sclerosis	0.000143	0.000324	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SPP1—multiple sclerosis	0.000142	0.000321	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL5—multiple sclerosis	0.000141	0.000319	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL5—multiple sclerosis	0.000141	0.000319	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR5—multiple sclerosis	0.000138	0.000313	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—multiple sclerosis	0.000137	0.00031	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—multiple sclerosis	0.000137	0.00031	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2RA—multiple sclerosis	0.000136	0.000308	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—multiple sclerosis	0.000135	0.000306	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SPP1—multiple sclerosis	0.000131	0.000296	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SPP1—multiple sclerosis	0.000131	0.000296	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR5—multiple sclerosis	0.000127	0.000288	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR5—multiple sclerosis	0.000127	0.000288	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—multiple sclerosis	0.000126	0.000284	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2RA—multiple sclerosis	0.000125	0.000284	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2RA—multiple sclerosis	0.000125	0.000284	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—multiple sclerosis	0.000124	0.000281	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—multiple sclerosis	0.000124	0.000281	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—multiple sclerosis	0.000121	0.000273	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	0.000117	0.000264	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	0.000117	0.000264	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—multiple sclerosis	0.000116	0.000262	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—multiple sclerosis	0.000116	0.000262	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000114	0.000258	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CD80—multiple sclerosis	0.000114	0.000257	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—multiple sclerosis	0.000112	0.000254	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—multiple sclerosis	0.000112	0.000253	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—multiple sclerosis	0.00011	0.000248	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—POMC—multiple sclerosis	0.000108	0.000244	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPC5—multiple sclerosis	0.000107	0.000241	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL2—multiple sclerosis	0.000106	0.000239	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CD80—multiple sclerosis	0.000105	0.000237	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CD80—multiple sclerosis	0.000105	0.000237	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—multiple sclerosis	0.000103	0.000234	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—POMC—multiple sclerosis	9.94e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—POMC—multiple sclerosis	9.94e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL2—multiple sclerosis	9.73e-05	0.00022	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL2—multiple sclerosis	9.73e-05	0.00022	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TYK2—multiple sclerosis	9.6e-05	0.000217	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—multiple sclerosis	9.52e-05	0.000215	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—multiple sclerosis	9.52e-05	0.000215	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RRM1—multiple sclerosis	8.84e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TYK2—multiple sclerosis	8.83e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TYK2—multiple sclerosis	8.83e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—multiple sclerosis	8.43e-05	0.000191	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—multiple sclerosis	7.99e-05	0.000181	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—multiple sclerosis	7.95e-05	0.00018	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—multiple sclerosis	7.56e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—multiple sclerosis	7.35e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—multiple sclerosis	7.35e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—multiple sclerosis	7.31e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—multiple sclerosis	7.31e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—multiple sclerosis	6.96e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—multiple sclerosis	6.96e-05	0.000157	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.86e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—multiple sclerosis	6.72e-05	0.000152	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—multiple sclerosis	6.24e-05	0.000141	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—multiple sclerosis	6.23e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—multiple sclerosis	6.18e-05	0.00014	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—multiple sclerosis	6.18e-05	0.00014	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—multiple sclerosis	6.11e-05	0.000138	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.89e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—multiple sclerosis	5.75e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—multiple sclerosis	5.75e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—multiple sclerosis	5.73e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—multiple sclerosis	5.73e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—multiple sclerosis	5.62e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—multiple sclerosis	5.62e-05	0.000127	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.37e-05	0.000122	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BCHE—multiple sclerosis	5.08e-05	0.000115	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—multiple sclerosis	4.69e-05	0.000106	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—multiple sclerosis	4.32e-05	9.77e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—multiple sclerosis	4.32e-05	9.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—multiple sclerosis	3.06e-05	6.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POMC—multiple sclerosis	2.62e-05	5.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—multiple sclerosis	2.39e-05	5.41e-05	CbGpPWpGaD
